Ascendis Pharma A/S
ASND
$158.82
-$2.71-1.68%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 393.95M | 391.82M | 354.67M | 343.38M | 356.22M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 393.95M | 391.82M | 354.67M | 343.38M | 356.22M |
| Cost of Revenue | 58.04M | 47.82M | 53.82M | 49.55M | 51.28M |
| Gross Profit | 335.92M | 344.00M | 300.86M | 293.83M | 304.94M |
| SG&A Expenses | 348.60M | 314.76M | 298.13M | 290.60M | 287.11M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 753.00M | 694.54M | 697.23M | 725.86M | 748.58M |
| Operating Income | -359.04M | -302.73M | -342.55M | -382.49M | -392.36M |
| Income Before Tax | -363.73M | -404.79M | -452.24M | -520.17M | -535.34M |
| Income Tax Expenses | 3.64M | 5.25M | 10.32M | 9.90M | 9.19M |
| Earnings from Continuing Operations | -367.37 | -410.04 | -462.57 | -530.08 | -544.53 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -367.37M | -410.04M | -462.57M | -530.08M | -544.53M |
| EBIT | -359.04M | -302.73M | -342.55M | -382.49M | -392.36M |
| EBITDA | -343.42M | -287.02M | -326.40M | -365.98M | -375.52M |
| EPS Basic | -6.29 | -7.14 | -8.10 | -9.35 | -9.64 |
| Normalized Basic EPS | -3.89 | -4.40 | -4.95 | -5.73 | -5.93 |
| EPS Diluted | -6.29 | -7.14 | -8.10 | -9.35 | -9.64 |
| Normalized Diluted EPS | -3.89 | -4.40 | -4.95 | -5.73 | -5.93 |
| Average Basic Shares Outstanding | 234.68M | 231.55M | 228.32M | 227.06M | 225.93M |
| Average Diluted Shares Outstanding | 234.68M | 231.55M | 228.32M | 227.06M | 225.93M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |